Sponsors (4)
The bill centralizes and accelerates VA adoption and rollout of promising mental-health therapies to expand veteran access and build evidence and workforce capacity, but does so with added federal cost, potential patient-safety and liability risks if evidence is limited, and the possibility of service disruptions or rushed planning.
Veterans will gain more organized, equitable, nationwide access to emerging PTSD and depression treatments through a dedicated VA office that coordinates evaluation and delivery.
VA system and veterans will benefit from centralized governance and a required national strategy (with timelines and facility/workforce assessments) to standardize rollout, reduce inconsistent access, and speed safe implementation across VA sites.
VA clinicians, researchers, and veterans will benefit from stronger support for rigorous research and workforce planning—identifying hiring and training needs and building an evidence base to improve future treatment standards.
Taxpayers and VA beneficiaries may face higher federal spending or reallocation of VA resources to create and operate a new office, potentially raising taxpayer costs or diverting funds from other VA programs.
Veterans and patients could be exposed to safety risks and uncertain effectiveness if novel therapies are emphasized or expanded before robust FDA evidence and oversight are in place, also raising potential liability concerns for providers.
Veterans and VA health systems risk service disruptions because implementing novel therapies may divert clinician time and facility space, and required upgrades and training could temporarily reduce access to existing mental-health care.
Based on analysis of 3 sections of legislative text.
Creates an Office of Novel Therapeutics in the VA and requires a national preparedness and implementation strategy within 180 days to plan rollout of emerging mental health therapies.
Introduced March 26, 2026 by Timothy Patrick Sheehy · Last progress March 26, 2026
Creates a new Office of Novel Therapeutics inside the Veterans Health Administration and requires the VA Secretary to deliver a national preparedness and implementation strategy within 180 days. The strategy must assess workforce and facility needs, set phased implementation timelines, identify barriers, and plan how the VA would evaluate and safely roll out emerging mental health treatments (including psychedelic-assisted therapies under FDA review). The law provides structure and planning requirements but does not appropriate funding or itself authorize clinical use of specific therapies.